



Annual Report

2024

EASL Office Home of Hepatology
7 rue Daubin
1203 Geneva, Switzerland
+41(0)22 807 03 60
easloffice@easloffice.eu
www.easl.eu

About Us

EASL, the European Association for the Study of the Liver, is a medical association dedicated to pursuing excellence in liver research, to the clinical practice of liver disorders, and to providing education to all those interested in hepatology.



Our Vision

Beating liver disease.
Promoting liver health.

Our Mission

To be the Home of Hepatology for everyone engaged in beating liver diseases.

We are committed to fostering awareness, prevention and the best possible patient care.

Our Strategic Pillars

E ducation

1. Enhance hepatology knowledge, skills, and competencies to improve patient care and outcomes.
2. Set the European standards for hepatology training and the application of Clinical Practice Guidelines.
3. Drive innovation through independent education, technology, and dynamic environments.
4. Promote career development, mentorship, and research opportunities.

A dvocacy

1. Shape liver health policy at European and global levels.
2. Raise public awareness and understanding of liver health.
3. Strengthen the voice of patient organisations.
4. Educate hepatologists and health professionals on public health and prevention.

S cience

1. Lead events to review and exchange science in the field of hepatology.
2. Advance medical science and patient care through high-quality research publications.
3. Drive evidence-based care with robust Clinical Practice Guidelines.
4. Champion impactful hepatology research projects, and integrate basic, translational, and clinical science across all EASL activities.

L eadership

1. Build an engaged EASL Community which reflects and represents the diverse global stakeholders dedicated to beating liver diseases.
2. Deliver valuable resources, opportunities, and services to enhance the professional growth of EASL members and the liver community.
3. Foster a strong interprofessional environment for cross-disciplinary collaboration.
4. Shape the future of hepatology through strategic partnerships.

EASL operates with a strong commitment to People, Purpose, and Planet, ensuring that our work positively impacts individuals, drives meaningful progress in liver health, and supports environmental sustainability. These values guide every decision, from our initiatives to our collaborations.

P eople

EASL values diversity, equality, and inclusion, fostering interdisciplinary collaboration to ensure accessible liver care for all. Our commitment is reflected in our EDI Policy, HR Policy, and updated Code of Conduct.

P urpose

EASL is committed to being fit for purpose, ensuring accountability, governance, and excellence in business practices. With strict process alignment, cost containment, and effective fundraising, we support our mission and serve our community with the highest standards.

P lanet

EASL prioritises sustainability, from energy-efficient operations and eco-conscious event design and partnerships. We strive to reduce resource consumption, prioritising local sourcing, and encouraging reuse and recycling wherever possible.

Our Values



Table of Contents

1.	Message from our Secretary General and Vice-Secretary	2
2.	EASL: Education	5
3.	EASL: Advocacy	10
4.	EASL: Science	15
5.	EASL: Leadership	21
6.	Financial Report	37
7.	Partners	44

MESSAGE FROM OUR SECRETARY GENERAL AND VICE-SECRETARY

This past year has been a remarkable period filled with achievements that have shaped EASL and strengthened our shared mission. Together, we have made tremendous progress in advancing liver health, thanks to the dedication and passion of each and every one of you.

EDUCATION remained a core priority in our mission. Our EASL Schools and the EASL-AASLD Masterclass in Savannah offered hands-on learning in supportive environments, shaping the future generation of hepatologists. The launch of the EASL Guidelines App marked a significant step forward in making clinical guidelines easily accessible, enhancing their practical use in daily practice.

Furthermore, we saw the production of EASL DeepDive, two new seasons of EASL Studio, CME-accredited eLearning courses, Molecular Tumour Boards, and Journal Clubs enriched our EASL Campus with cutting-edge resources—all freely available to empower our global community. In 2025 we witness the early stages of a new initiative aimed at improving training and quality of care, through the development of a European Core Curriculum in Hepatology, with the collaboration of UEMS and the European National Hepatology and/or Gastroenterology Associations.

ADVOCACY has remained a cornerstone of our work this year. We further strengthened global partnerships through initiatives such as the Healthy Livers, Healthy Lives coalition, which united international liver societies with a shared commitment. Our global awareness campaign for World Liver Day on 19 April reached unprecedented levels, highlighting the critical importance of liver health.

This year, EASL also took a firm stance in alcohol awareness, notably through the #AWARH24 campaign, advocating for mandatory alcohol labelling and stricter advertising regulations at the European Parliament.

We launched a new season of EASL Policy Dialogues, addressing key liver health issues such as rare disease equity, hepatitis elimination, and Non-Communicable Disease (NCD) advocacy. These dialogues continue to bridge the gap between science and policy, driving meaningful action.

We published a comprehensive policy statement addressing liver health in migrant populations, recognising the unique challenges these vulnerable groups face in accessing timely and effective healthcare.

The EASL-Lancet Commission remained dedicated to its mission of reducing liver-related mortality across Europe, promoting prevention, case-finding, and early diagnosis.

At the close of 2024, we co-hosted, in partnership with the WHO, the inaugural symposium of the European Alcohol Health Alliance, a medical coalition united in its advocacy for public health policies to mitigate the significant burden of alcohol-related harms in Europe.

SCIENCE has been the driving force behind our achievements this year, through the success of EASL Congress 2024 in Milan, and our improved offer for the upcoming EASL Congress 2025 in Amsterdam, via the implementation of a community wide assessment survey. Through smaller, focused events like the EASL Liver Cancer Summit 2024 in Rotterdam and its 2025 edition in Paris, and our SLD Summit 2025 in Estoril, our events provided platforms for deeper exploration of pressing issues in our specialty, fostering collaboration and innovation.

This year, EASL also led the way in shaping the future of liver research by hosting three high-impact consensus conferences—on MetALD, HCC, and PBC—bringing together global experts to redefine trial design, endpoints, and evidence frameworks in hepatology.

In 2024, EASL launched its inaugural AI Task Force, a strategic initiative bringing together leading experts to guide the responsible and impactful integration of artificial intelligence across research, education, clinical practice, and operations in hepatology, ensuring these advancements ultimately serve the needs of professionals, patients, and the broader public.

Meanwhile, our commitment to advancing research and knowledge through our hepatology publications has been unwavering. Our journals, Journal of Hepatology and JHEP Reports, both saw significant increases in their impact factors to 26.8 and 9.5 respectively, serving as premier platforms for groundbreaking discoveries. We also published four new Clinical Practice Guidelines in 2024 and two in 2025, providing essential tools for clinicians worldwide.

LEADERSHIP within EASL continues to drive our mission forward, with our membership now exceeding 7,700 individuals: a testament to our expanding community. This year, our mentorship programme successfully paired five mentee-mentor pairs, fostering the education of the next generation and nurturing the transfer of expertise and leadership within hepatology. We encouraged a global and united voice for hepatology through our strong partnerships with global liver societies worldwide, ALEH, AASLD, APASL, SOLDA and national associations.

We extend our heartfelt gratitude to every member of our EASL community—governing board members, committees, Task Forces, industry and patient representatives, sister societies, and partners. Interdisciplinary collaboration, especially through partnerships with other societies and medical specialties, continues to strengthen our collective impact and enrich the field of hepatology.

Your dedication and collaboration have been instrumental to our successes and continue to inspire us to achieve even more.

This annual report marks a moment of transition, as Aleksander Krag concludes his term as EASL Secretary General, and Debbie Shawcross prepares to begin hers at the upcoming congress. It reflects not only on the achievements of the past term but also looks ahead to the future direction and continued growth of EASL.

As we write the EASL Congress is just weeks away, we invite you to join us at the EASL General Assembly on 9 May 2025, from 18:45 to 19:45, in Paumgartner room, for an update on progress to date and perspectives for the coming years.



SECRETARY GENERAL
Aleksander Krag



VICE-SECRETARY
Debbie Shawcross

Education

EASL is dedicated to being the leading independent and relevant resource for education and professional development in liver health and research. Our range of formats, from online platforms to training opportunities, cater to basic scientists, healthcare professionals at all levels as well as patients. Our initiatives aim to enhance knowledge, skills, and competencies in hepatology, ultimately improving patient care.

E






EASL CAMPUS



EASL Campus is an extensive online platform providing access to a wealth of educational resources. It includes in-depth and flexible learning through webinars, on-demand posters and webcasts from EASL events. CME accredited courses provide the community with essential knowledge to stay up-to-date on the latest clinical practice.

EASL CAMPUS METRICS 2024



A new CME-accredited educational webinar series which provides in-depth, high-quality educational resources on hepatology topics.



A session that explores the role of genetics in liver diseases, providing insights into diagnosis, management, and treatment strategies.



A means to engage with the latest research published in EASL's high-impact journals, featuring discussions on selected articles.



An interactive learning tool designed to test and enhance knowledge in hepatology through engaging, case-based questions.



An expert-led educational session on the molecular profiling of liver tumours to guide personalised treatment and improve patient outcomes.



EASL offers online courses through EASL Campus, enabling participants to earn CME credits across various hepatology topics.



EASL STUDIO

Aleksander Krag, Odense University Hospital, Denmark

Debbie Shawcross, King's College London, UK

Thomas Berg, University of Leipzig, Germany

Ahmed Elsharkawy, Queen Elizabeth Hospital, UK

Paolo Angeli, University of Padova, Italy

Maria Buti, Vall d'Hebron Barcelona Hospital, Spain

Kathryn Jack, Nottingham University Hospitals NHS Trust, UK

Rajiv Jalan, University College London, UK

Verena Keitel, University Hospital Magdeburg, Germany

Pierre-Emmanuel Rautou, Beaujon Hospital, Clichy & Paris-Cité University & INSERM, France

Thomas Reiberger, Medical University of Vienna, Austria


Pedro Rodrigues, Biodonostia Health Research Institute, San Sebastian, Spain

Anna Saborowski, Hannover Medical School, Germany

Oren Shibolet, Tel-Aviv Medical Center and Tel-Aviv University, Israel

Shira Zelber Sagi, School of Public Health, University of Haifa & Tel Aviv Medical Center, Israel

EASL Studio is a weekly, digital initiative with live broadcasts featuring interviews, debates, and roundtables. Liver disease and research experts have discussions on multidisciplinary topics. EASL events offer special live editions bringing the latest news and highlights in hepatology.



EASL SCHOOLS

EASL Schools help train the next generation of hepatologists and scientists. Through individual work, collaborative teamwork and discussions with faculty, students gain invaluable insight into new experimental techniques and clinical approaches.

Steatotic Liver Disease – from pathogenesis to treatment

- 26-27 April 2024, Aarhus, Denmark, 25 students from 14 countries
- Organisers: Jacob George, Henning Grønbaek and Karen Louise Thomsen

Interpretation of liver biopsies for young hepatologists

- 12-13 April 2024, Barcelona, Spain, 20 students from 11 countries
- Organisers: Alba Díaz and Xavier Forns

Personalised medicine in hepatobiliary malignancies

- 26-27 April 2024, Aarhus, Denmark, 22 students from 12 countries
- Organisers: Anna Saborowski, Peter Schirmacher, Arndt Vogel and Thomas Longerich

Precision cut liver slices and liver organoids - versatile ex-vivo models of liver disease

- 2-4 October 2024, London, United Kingdom, 25 students from 11 countries
- Organisers: Shilpa Chokshi, Luca Urbani and Elena Palma



EASL MENTORSHIP PROGRAMME

The EASL Mentorship Programme guides young scientists and clinicians through a crucial stage in their career path by encouraging scientific exchange and fostering personal developmental relationships with a more experienced and knowledgeable hepatologist or senior scientist. In 2024, this initiative brought together five mentor - mentee pairs.



Bastian Engel



Ahmed Elsharkawy



Joost Boeckmans



Jörn Schattenberg



Ferya Çelik



Nuria Fabrellas



Marta Alonso



Verena Keitel



Pavitra Kumar



Krista Rombouts

Advocacy

EASL's advocacy initiatives are focused on elevating the standards of hepatology care and access for patients, driving public health policy change, and augmenting public awareness about liver diseases. These efforts encompass a variety of activities, each targeting specific aspects of liver health advocacy and public education.

A



EASL POLICY DIALOGUES

EASL Policy Dialogues discuss policy issues related to liver health, combining scientific and policy perspectives from experts. This initiative raises awareness of EASL's advocacy priorities and engages various stakeholders.

EASL - LANCET COMMISSION

In 2021, the first EASL-Lancet Commission addressed the rising burden of liver disease in Europe, proposing ten evidence-based recommendations to shift from end-stage care to prevention and health promotion. Building on this, the second EASL-Lancet Commission, launched in 2023, focuses on implementing these recommendations, addressing structural challenges, and tracking progress to improve liver health across Europe.

HEALTHY LIVERS, HEALTHY LIVES COALITION

EASL, along with AASLD, ALEH, APASL, and SOLDA founded this global coalition which facilitates collaboration on global liver health issues, advocating for policy and clinical changes.

MEP FRIENDS OF THE LIVER GROUP

An interest group at the European Parliament coordinated by EASL, it raises awareness and puts liver health higher on the political agenda. The initiative supports the EASL-Lancet Liver Commission's call for a shift to prevention and early detection.

EASL LOVE YOUR LIVER

Love your Liver was first launched in 2022, aimed at raising awareness for liver health, tailored to local communities hosting EASL Congresses. This initiative strives to promote early detection and care, and build local professional capacities in hepatology.

Love Your Liver unfolded across Milan and other Italian cities during the EASL congress and throughout June. Schoolchildren participated in interactive sessions with hepatologists to learn about the importance of liver health, and both the public and congress participants were screened for liver stiffness, MASLD, and HCV.





Taking place every 19 April, this initiative for the general public focuses on raising awareness on liver diseases, aiming to promote prevention, enhance screening strategies, and improve access to treatment. worldliverday.org



In 2024 the campaign reached all continents, and individuals, hospitals, research centres, patient organisations, EU-funded projects, Consortia, universities, and industry posted on social media, printed materials, carried out screening and testing campaigns, held lectures and webinars, spread vaccination calls to action, and walked or exercised for liver health.



EASL PATIENT SYNERGIES

EASL actively collaborates with 10 patient organisations, building strong partnerships to amplify the voices of those affected by liver diseases. Together, we raise awareness, advocate for better healthcare policies, and promote initiatives that improve liver health and support for patients and their families across Europe.




EASL EU- FUNDED PROJECTS

EASL supports the dissemination and exploitation work package for several Horizon-Europe and Horizon-2020 projects.



EASL POLICY STATEMENTS

EASL's policy statements address key challenges in liver health, offering evidence-based recommendations to guide policymakers and stakeholders. These documents aim to influence healthcare policies, prioritise liver disease prevention, and improve access to diagnosis and treatment.



In 2024, EASL published a policy statement on addressing the liver health needs of migrant populations in Europe.

Read all policy statements on:
<https://easl.eu/publications/easl-policy-statements/>

S

Science

EASL provides an efficient and highly respected environment for scientific information, communication and knowledge-exchange in the field of the study of the liver. It builds links between stakeholders, pushes scientific frontiers and raises the standards for professionalism, networking, dedication and innovation.



Journal of Hepatology Editorial Board

The Journal of Hepatology is a monthly, English language, peer-reviewed journal. First published in 1985 as the official journal of EASL, it provides an international forum for the publication of original articles, reviews and letters to the Editor describing basic laboratory, translational, and clinical investigations in hepatology.

This year the Journal of Hepatology achieved exceptional results with a 2023 impact factor of 26.8, solidifying its status as the premier hepatology-only journal.

Prof. Vlad Ratziu has been appointed as the Editor-in-Chief, bringing decades of expertise to advance liver research and education globally.



Vlad Ratziu
Editor-in-Chief



Frank Tacke
Co-Editor



**Heiner
Wedemeyer**
Co-Editor



**Lorenza
Rimassa**
Co-Editor



Phil Newsome
Senior Editor



Tom H. Karlsen
Co-Editor



**Annalisa
Berzigotti**
Co-Editor



JHEP Reports Editorial Board

JHEP Reports is an open-access companion title to the highly-respected Journal of Hepatology. It publishes original papers, reviews, and letters to the Editor concerned with basic, translational, and clinical research in the field of hepatology. JHEP Reports is an innovative journal publishing articles on global issues in hepatology.

JHEP Reports achieved an impressive impact factor of 9.5 in the 2024 release of Journal Citation Reports (JCR) by Clarivate. This notable accomplishment underscores the journal's growing influence and recognition as one of the leading publications in the field of hepatology.



Josep M. Llovet
Editor-in-Chief



Javier Fons
Deputy Editor



Arndt Vogel
Co-Editor



**Sophie
Lotersztajn**
Co-Editor



Jacob George
Co-Editor







**Virginia
Hernandez-Gea**
Co-Editor



EASL CLINICAL PRACTICE GUIDELINES

EASL's Clinical Practice Guidelines assist physicians, healthcare providers, patients and other interested parties in the clinical decision-making process. The EASL Guidelines present a range of state-of-the-art approaches for the diagnosis and treatment of liver diseases.

Four new EASL CPGs were published in 2024.



At EASL Congress 2024 we unveiled the new EASL Guidelines app. This is an indispensable mobile tool that empowers clinicians to bolster clinical decision-making processes, access essential resources conveniently, and continuously expand knowledge.

Featuring calculators and scores, the app aids in assessments and prognostic evaluations, allowing practitioners to derive precise insights and optimise patient management strategies. The EASL Guidelines app also grants access to EASL Clinical Practice Guidelines, ensuring users stay updated on evidence-based recommendations and best practices in hepatology.



EASL SUMMITS


EASL Summits are a series of smaller, focused meetings that occur throughout the year, each dedicated to specific topics within the spectrum of hepatology. These summits, such as the SLD Summit concentrating on Steatotic Liver Disease and the Liver Cancer Summit which delves into liver tumors, provide targeted and in-depth exploration of their respective areas.



EASL Liver Cancer Summit 2024 Rotterdam and online 22-24 February


539 delegates from 48 countries, 151 abstracts

A comprehensive summit that delved into current knowledge and future directions in hepatocellular and cholangiocellular carcinoma, covering advances in pathogenesis, early detection, multidisciplinary therapies, and staging.



EASL Congress 2024

The EASL Congress is the premier event in hepatology, held annually and distinguished as the largest of its kind in Europe. It offers a rich programme of hands-on learning sessions and top level lectures conducted by world-renowned faculty.



EASL Congress 2024
Milan and online 5-8 June

DELEGATES

7,809
registrations
from

104
COUNTRIES



118

Oral presentations





2,534

Abstracts submitted



1,712

Posters



Leadership

EASL is a globally recognised community of people committed to improving liver health and research. Speaking as the unified voice of European hepatology, we help shape the healthcare landscape worldwide.



Governing Board

The EASL Governing Board is the leadership body responsible for steering the strategic direction of the association. Committed to advancing liver health worldwide, the Governing Board oversees EASL's activities, ensures alignment with its mission, and upholds the highest standards of governance, transparency, and accountability. The board drives EASL's impact and growth as a global reference in hepatology.

- We express our deepest gratitude to Francesco Negro, our exiting Treasurer, and Maria Buti, our exiting Public Health Councillor. Their dedicated service has greatly contributed to the success of our Governing Board.
- We welcomed Massimo Pinzani and Shira Zelber-Sagi in these two instrumental positions in our Governing Board.



Aleksander Krag
Secretary General



Debbie Shawcross
Vice-Secretary



Massimo Pinzani
Treasurer



Sven Francque
Educational
Councillor



Shira Zelber-Sagi
Public Health
Councillor



**Francesco
Paolo Russo**
External Affairs
Councillor



**Ahmed
Elsharkawy**
Internal Affairs
Councillor

Scientific Committee

The Scientific Committee plays a key role in advancing EASL's mission by providing expertise and guidance to ensure rigorous standards in scientific research and programming. It oversees the development and review of scientific content for EASL's events, Clinical Practice guidelines, fellowships and grants supporting innovation and excellence in hepatology.

- Nominations and appointment of three new members: Sabela Lens, Cyrielle Caussy, and Matthias Pinter.



Rui Castro
Portugal



Cyrielle Caussy
France




**Sarwa Darwish
Murad**
the Netherlands



Sabela Lens
Spain



Ana Lleo
Italy



Matthias Pinter
Austria



Bogdan Procopet
Romania



Eric Trépo
Belgium

Educational Committee

The Educational Committee supports EASL's mission to remain a global leader in liver-related education by offering scientific expertise and strategic guidance. It oversees the development and monitoring of a high-quality educational portfolio aligned with EASL's educational strategy.

- Nomination and appointment of Jesus Bañales, Shilpa Cholkshi, and Massimo Iavarone.



Sven Francque
Belgium



Henning Grønnebæk
Denmark



Krista Rombouts
United Kingdom



Rajeshwar Mookerjee
United Kingdom



Massimo Iavarone
Italy



Shilpa Cholkshi
United Kingdom



Verena Keitel
Germany

Policy, Public Health and Advocacy Committee

The PPHA Committee drives EASL's efforts to influence policy, promote public health, and advocate for improved liver health on a global scale. The committee ensures that liver health remains a priority in public health agendas and fosters meaningful change for patients and communities worldwide.

- Nomination and appointment of Shira Zelber-Sagi as Public Health Councillor.
- Nomination and appointment of Richard Parker, Mathis Heydtmann and José Willemse as members of the PPHA Committee.



Shira Zelber-Sagi
Public Health
Councillor, Israel



José Willemse
the Netherlands



Mathis Heydtmann
Germany



Richard Parker
United Kingdom



Loreta Kondili
Italy



Frank Murray
Ireland



Jörn Schattenberg
Germany

Ethics & Compliance Committee

The EASL Ethics Committee plays a pivotal role in upholding the highest standards of integrity, transparency, and accountability within the association. It ensures that EASL's policies, practices, and initiatives align with ethical principles, fostering trust and fairness in all our activities and collaborations.

- Yearlong monitoring and management of interests at EASL leadership level.
- Regular review of Clinical Practice Guidelines panels.
- Engagement in BioMed Alliance Europe's Code of Conduct Working Group.



Mark Thursz
United Kingdom



Tom Luedde
Germany



Marina Berenguer
Spain



Valérie Paradis
France



Herbert Tilg
Austria

Young Investigators Task Force

The Young Investigators (YI) Task Force fosters a dynamic community of early-career hepatologists, promoting EASL activities, facilitating knowledge exchange, and organising exclusive events like the YI social at the EASL Congress. It advises the Governing Board on educational initiatives and supports YIs through tailored activities, inspiring the next generation of hepatologists.

- We welcomed 3 new members: Mads Israelsen, Alberto Zanetto, and Carolin Schneider.
- Dedicated YIs Symposium and YI-led workshops at EASL Congress 2024.
- Selection of two recipients of the 2023 Emerging Leader Award: Sabela Lens and Luke Boulter



Marta Alonso
Spain



Mads Israelsen
Denmark




Thomas Marjot
United Kingdom



Pedro Rodrigues
Spain



Carolin
Schneider
Germany



Alberto Zanetto
Italy

Nurses and AHPs Task Force

The Nurses and Allied Health Professionals (AHP) Task Force supports the integration and advancement of nurses and AHPs within the EASL community. By organising dedicated sessions and events, and facilitating tailored educational initiatives the task force ensures that nurses and AHPs have a strong voice and role in shaping the future of liver health.

- We welcomed Catarina Lindqvist to the task force.
- Full day Nurse & AHP Forum at EASL Congress 2024.
- The Rising Star Award at EASL Congress 2023 was awarded to Amy Teague. This award aims to recognise excellence in nurses and Allied Health Professionals in hepatology.



**Malene Barfod
O'Connell**
Denmark



Sonja Beckmann
Switzerland



Nuria Fabrellas
Spain



Kate Hallsworth
United Kingdom



Gemma Iserte
Spain



**Catarina
Lindqvist**
Sweden



Denise Schäfer
Austria

Basic Science Task Force

The Basic Science (BS) Task Force promotes the vital role of basic and translational research in advancing liver health. It bridges the gap between research and clinical practice by sharing findings with the EASL community and collaborating with clinicians to address unmet needs. The task force also designs dedicated basic science sessions at the EASL Congress.



Marta Afonso

Portugal



Jesus Bañales

Spain



Rui Castro

Portugal



Ana Lleo

Italy



Pedro
Rodrigues

Spain



Krista
Rombouts

United Kingdom



Saskia Van Mil

the Netherlands

Artificial Intelligence (AI) Task Force

The EASL AI Task Force is dedicated to leveraging artificial intelligence to transform hepatology. Comprised of experts, it focuses on advancing research, enhancing education, supporting clinical decision-making, optimising events and journals, fostering industry collaboration, and improving operational efficiency. By harnessing AI responsibly, the task force aims to benefit EASL members, patients, and the wider community.

- The AI Task Force advises the EASL Governing Board in Research, Education, Clinical decision making, EASL events, Journals, and industry collaboration



Julien Calderaro
France



Jakob Kather
Germany



Tom Luedde
Germany



Thomas Marjot
United Kingdom



Raquel Perez-Lopez
Spain



Debbie Shawcross
United Kingdom



Ashley Spann
USA



Eric Trépo
Belgium

EASL Office 2024

Management & Administration



Ben Hainsworth
Executive Director



Laurence Comont
Executive Assistant



Sophie Fux
Human Resources

Finance & Administration



Mehdi Boudjani



Estelle Pappes

Publications



Joel Walicki



Duncan
Anderson



Sarita
Bhattacharya



Kristina
Jajcevic



Pablo
Echeverria

Education



Laurent Perrin



Elinam Gayi



Laura Daguerre



Matthias Girod



Sofia Damachi

Scientific Programme



Patricia
Pochelon



Rocio Davina



Katerina
Katsarou



Céline Santo

Policy and Public Health



Irene Mosqueira



Maraika Black



Kelena
Matthews

Events



Carina Schmidt



Claire
Chombeau



Christophe
Abetinot

Business Development



Olga Krüger



Laudina
Asomaning



Gisela Valky-
Pons



Géraldine
Fankhauser



Naomi
Siguenza

Association and Community Services



Wouter Kruijs



Oliver Cole



Adonia Dhanjal



Chiara
Hartmann

EASL fosters a workplace that is as diverse, equitable, and inclusive as it is forward-thinking and environmentally conscious. In 2024, we boast a team of 33 dedicated staff members, of which 24 are female and 9 male. Our team is as varied as it is skilled, representing 15 different nationalities, fluently conversing in 16 languages, with 9 staff members holding scientific doctorates. We have seen a positive impact on our workforce through flexible working hours and the possibility of remote work, boosting productivity and reinforcing the association's dynamism.

Community & Membership

EASL engages globally with all stakeholders in the liver field, regional sister societies, national associations, and related organisations. We encourage the spreading of knowledge and expertise in best practices and the latest scientific breakthroughs in hepatology to all those interested in the liver and its disorders.




Let's unite
Hepatology

*Discover your
membership benefits!*



Become a member today

This year marked another strong period of growth for EASL, with membership surpassing 7,700 in 2025 and our MyEASL Community reaching over 56,800 individuals across 175 countries. Through active participation in international congresses like ALEH, APASL, AASLD, AISF, AEEH, and UEG, we continue to strengthen connections with the global hepatology community. Our inclusive membership model focuses on supporting the next generation of hepatologists, nurses, allied health professionals, and patients—offering reduced fees for trainees and professionals from emerging economies, and free membership for those from resource-limited regions. New benefits include priority access to congress sessions, exclusive content, and easier auto-renewal options. We are deeply grateful to our members—the heart of EASL—for their continued trust and dedication to advancing hepatology together.




LEADING COUNTRIES IN EASL MEMBERSHIP


123
countries

7,789
members

37
national
associations



EASL SOCIAL MEDIA METRICS AS OF MARCH 2025



EASL Awards 2024

Each year at the EASL Congress, we honour outstanding individuals whose work has significantly advanced the field of hepatology. From pioneering scientists and clinical experts to rising young investigators and dedicated healthcare professionals, the EASL Awards shine a spotlight on excellence across the liver community. These prestigious honours are presented annually in front of the global liver community—celebrating those who are writing the future of hepatology.



EASL Recognition Awards 2024

The first EASL Recognition Awards were presented at the 41st Annual Meeting in Vienna in 2006. The initial recipients reflected the core aims of the awards: to recognise dedicated scientists who have made meaningful advances in research, clinical care, and education within their area of expertise. Since then, EASL has continued to recognise individuals whose work has contributed to the progress of hepatology.



Tom Hemming Karlsen



Christian Bréchet



Norah Terrault

EASL International Liver Health Advocacy Awards 2024

This award recognises individuals who have made a significant impact in raising awareness, improving public understanding, or advancing policy in support of liver health. The EASL International Liver Health Advocacy Award honours efforts that extend beyond the scientific community, highlighting meaningful contributions to liver disease prevention, education, and advocacy at a national or global level.



Manal El-Sayed



Wendy Spearman

EASL Emerging Leader Awards 2024

The EASL Emerging Leader Award is a yearly award specifically dedicated to young fellows, up to 40 years of age, who are active members of EASL. Every year, two Young Investigator Awardees are elected, based on their international liver research achievements to date.



Sabela Lens



Luke Boulter

EASL Rising Star Award 2024

With this initiative, the task force recognises exceptional liver nurses and AHPs who contribute to service, clinical excellence, leadership, audit, innovation, education, and research.



Amy Teague

EASL Daniel Alagille Award 2024

The Daniel Alagille Award is given to a promising, young scientist, exploring the frontiers of paediatric or adult genetic cholestatic diseases. The award is supported by Theravia.



Sarina Shabso

Treasurer's report

Dear members,

It is my honour to present the Treasurer's Report on [EASL's 2024 financial results](#).

In the context of two consecutive years of financial losses – EUR 3,188,912 in 2022 and EUR 1,433,193 in 2023 – EASL launched the Business Analysis Task Force. This initiative aimed to restore financial balance and lay the foundations for sustainable growth. The 2024 budget, approved by members in November 2023, was built on this objective. Since then, EASL's leadership and staff have worked together to honour the Task Force's commitments, exceed financial goals, and deliver on the core strategic objectives of our association.

The 2024 budget was based on the following guiding principles:

- Consolidate services and value provided to members,
- Achieve a break-even result,
- Enable recovery and consolidation,
- Exercise prudence in financial planning

Accordingly, the following measures were applied:

- Rescaling event formats,
- Reducing fixed expenses,
- Reducing EASL Office headcount,
- Cutting discretionary operating expenses,
- Rescheduling or cancelling smaller events,
- Pausing investment-intensive projects.

With a [net profit of EUR 2,320,903 \(CHF 2,210,387\)](#), the result for 2024 confirms a remarkable turnaround.

This positive result is explained by the operational (EBIDTA) expenses being 5% below budget and the operational (EBIDTA) income exceeding budget by 11%.

Several activities outperformed budget expectations:

- **EASL Congress 2024:** Higher attendance was paired with increased sponsorship revenues and significant savings.
- **EASL Liver Cancer Summit 2024:** Although attendance was slightly lower than planned, sponsorship income and cost control led to better-than-expected results.
- **EASL SLD Summit:** No event was held in 2024, in line with cost containment decisions.
- **Education:** Although expenses slightly exceeded the budget (EUR 265,791 vs. EUR 240,046), this was more than offset by a significant increase in income (EUR 966,175 vs. budgeted EUR 660,000), driven by the development of new products, the extension of existing ones, and increased sponsorship sales — resulting in a margin of EUR 700,385.
- **Association & Community Services:** Income reached EUR 806,378, exceeding the initial budget of EUR 704,500 by 14%, resulting in a margin of EUR 519,521.
- **Publishing:** Income reached EUR 1,375,800, exceeding the initial budget of EUR 1,320,000 by 4%, while expenses amounted to EUR 629,064 (12% below budget), resulting in a margin of EUR 746,744.
- **Policy, Advocacy & Public Health:** 2024 marks the first year these activities contribute positively to the EASL business model. While expenses exceeded the budget by 15% due to expanding workstreams, total sponsorship revenues were 20% above budget, resulting in a margin of EUR 76,188.

Operational expenses in core support functions were carefully managed. Overheads were maintained at a stable level and represented 5% of the total EBIDTA expenses. EASL Payroll costs decreased compared to 2023, reflecting the budgeted reduction in headcount.

Extraordinary and non-cash items also contributed to the overall positive result but with significant year-on-year variation. In 2023, the provision for VAT on the 2022 London Congress totalled EUR 612,461. In 2024, this item was no longer applicable, resulting in a reduced burden (total extraordinary expenses in 2024: EUR 451,205).

This positive result also reinforces EASL's reserves, which now stand at CHF 9,189,417 (equivalent to EUR 9,792,122) compared to CHF 7,085,586 as of 31.12.2023 (equivalent to EUR 7,621,368). This strengthened position ensures improved resilience and capacity to invest in the association's long-term priorities.

It is also important to note that, as of 2024, EASL's financial statements are now presented in Swiss francs (CHF), further aligning our reporting with the association's legal framework.

Importantly, the EASL Office is actively implementing a robust Internal Control System. In 2024, we engaged a new external auditor – KPMG, one of the Big Four – to conduct our limited statutory audit. Their conclusion has been:

“Nothing has come to the auditor’s attention to suggest that the Financial Statements are not in compliance with Swiss law and the Association’s Articles.”

This is the highest level of assurance available under a limited statutory audit and reflects the integrity and diligence with which EASL manages its finances.

I would like to sincerely thank the Office team, our Secretary General, and all members who have contributed to this achievement. Together, we have laid the groundwork for a financially sustainable future for EASL.

Yours faithfully,



Massimo Pinzani
EASL Treasurer

2024 Financial Statements

Balance sheet

Assets		2024	2023
	Note	CHF	CHF
Current assets			
Cash and cash equivalents		1,728,113	635,766
Accounts receivables and other receivables	*Note 1	4,140,933	2,040,010
Prepaid expenses and accrued income	*Note 2	824,148	575,481
Financial assets		417,532	-
Total current assets		7,110,726	3,251,257
Non-current assets			
Financial assets		2,952,202	3,418,351
Property, plant and equipment		4,114,092	4,373,877
Intangible assets		95,639	86,320
Total non-current assets		7,161,932	7,878,548
Total assets		14,272,659	11,129,804
Liabilities and reserves			
		CHF	CHF
Current liabilities			
Accounts payable		374,792	908,015
Other short-term liabilities		216,767	310,716
Deferred income and accrued expenses	*Note 1	3,040,585	1,454,387
Total current liabilities		3,632,144	2,673,118
Non-current liabilities			
Long-term provisions		1,341,197	1,335,601
Restricted funds		109,900	35,500
Total non-current liabilities		1,451,097	1,371,101
Reserves			
Voluntary retained earnings		1,344,530	2,681,712
Reserve fund		5,634,500	5,634,500
Translation difference		-	161,937
Profit/(Loss) for the year		2,210,387	-1,392,563
Total reserves		9,189,417	7,085,586
Total liabilities and reserves		14,272,659	11,129,804

2024 Financial Statements

Profit and loss account, as of 31 December 2024

	Note	2024 CHF	2023 CHF
Operating income			
Events		8,983,853	8,775,590
Education		911,597	369,814
Association & Community Services (including membership)		765,646	789,479
Publishing		1,353,937	1,304,194
Policy, Public Health and Advocacy		189,943	124,916
Total operating income		12,204,976	11,363,994
Operating expenses			
Events		-4,457,137	-5,497,261
Education		-265,433	-263,144
Association & Community Services (including membership)		-283,361	-495,590
Publishing		-568,417	-575,103
Policy, Public Health and Advocacy		-127,782	-216,631
Governance		-366,102	-370,691
Scientific Programme		-311	-
Business Development		-3,440	-
Total operating expenses		-6,071,984	-7,418,420
Personnel expenses		-3,583,115	-3,984,362
Administrative expenses			
IT		-261,193	-191,721
Human resources		-53,536	-98,656
Finance		-110,850	-93,866
Administration & office		-77,459	-114,498
Total administrative expenses		-503,038	-498,742
Depreciation and amortisation on property, plant and equipment		-275,950	-255,574
Operating result		1,770,890	-793,106
Financial income and expenses			
Financial expenses		-36,071	-57,414
Financial income		178,225	61,919
Foreign exchange result		267,052	-326,817
Other financial expenses		-	-
Total financial income and expenses		409,205	-322,311

2024 Financial Statements

Profit and loss account, as of 31 December 2024

	Note	2024 CHF	2023 CHF
Non-operating income and expenses			
Building operating revenue		20,711	19,127
Expenses on building EASL		-	-520
Non-operating income and expenses		20,711	18,607
Extraordinary, non-recurring or prior-period expenses	<i>*Note 3</i>	-117,699	-724,774
Extraordinary, non-recurring or prior-period income	<i>*Note 3</i>	127,281	430,288
Profit/(Loss) before taxes		2,210,387	-1,391,293
Direct taxes		-	-1,270
Profit/(Loss) of the year		2,210,387	-1,392,563

2024 Financial Statements

Notes to the 2024 financial statements

EASL, the European Association for the Study of the Liver ("EASL"), founded in 1966, registered in Geneva since 2018, is a medical association dedicated to pursuing excellence in liver research, to the clinical practice of liver disorders, and to providing education to all those interested in hepatology. Its vision is to beat liver disease and promote liver health. Its mission is to be the Home of Hepatology for everyone engaged in beating liver diseases and is committed to fostering awareness, prevention and the best possible patient care. This mission is carried out through four strategic pillars: Education, Advocacy, Science, and Leadership.

General principles

General aspects

These annual financial statements were prepared according to the principles of the Swiss Law on Accounting and Financial Reporting (32nd title of the Swiss Code of Obligations). Where not prescribed by law, the significant accounting and valuation principles applied are described below. It should be noted that to ensure the company's going concern, the company may create or release hidden reserves.

Financial assets

Financial assets with a short-term holding period are valued at their quoted market price as at the balance sheet date. No valuation adjustment reserve was created.

Financial assets with a long-term holding period are valued at their acquisition cost adjusted for impairment losses.

Recognition of revenue

The main revenue stream of EASL is sponsorship & registration fees for Events, mostly from EASL Congress and the EASL Liver Cancer Summit. Revenue related to events is recognized in the financial year in which the event occurs.

EASL generates other revenues from the Education portfolio, the Policy, Public Health and Advocacy portfolio, the Publishing portfolio as well as EASL membership fees.

Membership fees are recognised in the accounting period in which the fees relate to.

Non-current assets and leases

Property, plant, and equipment are valued at purchase cost, less any depreciation required by generally accepted accounting principles. Depreciation is charged on a straight line basis over the useful life of the fixed asset. The assets' residual values and useful lives are reviewed, and adjusted if appropriate, at the end of each reporting period.

Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in the income statement.

The useful lives of assets have been determined as follows:

Type of assets	Useful life
Building	30 years
Furniture, Fixtures and Equipment	10 years
Computer & Hardware	3 years
Intangible Assets	3 years

Direct taxes

EASL benefits from an exemption on direct taxes for an indefinite period

2024 Financial Statements

Currency and Presentation Note - 2024

The functional currency is the Swiss franc (CHF), and the accounts are maintained in CHF. The financial statements are prepared using the historical cost convention, and all financial information is presented in CHF.

Operations in foreign currencies are converted as follows:

- Monetary assets and liabilities are translated at the closing exchange rate at the reporting date.
- Transactions during the year are converted at the exchange rate in effect on the transaction date.
- Exchange gains and losses resulting from the settlement of such transactions or from the conversion of monetary items at year-end rates are recognized in the income statement.

In 2023, the Association changed its reporting presentation to show financial statements solely in CHF, discontinuing the parallel presentation in EUR used in previous years. As 2024 marks the second year of reporting under this CHF-only presentation, EUR figures are no longer included.

Comparative amounts

Certain comparative financial information have been reclassified to conform to the current year's presentation.

Details, analyses, and explanations to the financial statements

The number of full-time equivalents did not exceed 50 on an annual average basis in the current and prior year.

Receivables and liabilities

Receivables and liabilities towards direct or indirect participants and management bodies and entities in which there is a direct or indirect participation must in each case be shown separately on the balance sheet or in the notes to the financial statements (art. 959a para. 4 CO). This only applies if these items are not presented in the balance sheet as suggested.

Pension liabilities

On 31 December 2024, as on 31 December 2023, there were none, as payments were done before the end of the year.

Collateral for third-party liabilities

	2024	2023
Guarantee obligations	68,507	67,868

Total amount resulting from the dissolution of replacement reserves and the material dissolution of excess hidden reserves

No hidden reserves were released in the current year and in the prior year.

Subsequent events

There have been no significant events impacting the 2024 annual accounts between the balance sheet date and the date of signing the financial statements.

Fees paid and accrued to the auditor

Audit services	22,418	25,226
----------------	--------	--------

2024 Financial Statements

Note 1:

Accounts receivables and other receivables & Deferred income and accrued expenses

As of 31 December 2024, an amount of CHF 2 647 215,07 recorded under accounts receivable and deferred income relates to future commitments from clients for events scheduled in 2025. This amount will be recorded as an income in 2025.

This note does not reflect a change in accounting policy but serves as a clarification in light of the increased balance compared to prior years. The rise is primarily due to the earlier contractual setup and invoicing of 2025 events, which occurred ahead of previous timelines.

These receivables are valued at their nominal values. Credit default risks are accounted for by specific and general allowances. General allowances are recognised for items that have not yet been considered with a specific allowance. The general allowance is based on the assumption that the default risk increases as the debt becomes increasingly overdue.

Note 2:

Prepaid expenses and accrued income

A prepaid expense results from a business making advanced payments for goods or services to be received in the future. Prepaid expenses are initially recorded as assets, but their value is expensed over time onto the income statement. After the benefits of the assets are realized over time, the amount is then released to P&L (i.e. recorded as an expense). Prepaid expenses are, in nature, short term assets. However, for the needs of EASL business model, it can occur that some advanced payments for goods or services will be received in the mid-term future (i.e. two to five years ahead).

	2024	2023
- Prepaid expenses	824,148	506,668
- Accrued income	0	68,812
Prepaid expenses and accrued income	824,148	575,481

Note 3:

Explanations of extraordinary, non-recurring or prior-period items in the profit and loss statement

	2024	2023
Extraordinary, non-recurring or prior-period expenses		
Prov. 2022 UK VAT (VAT + Interest + Penalty)	-	-603,843
Other	-117,699	-120,930
Total extraordinary, non-recurring or prior-period expenses	-117,699	-724,773
Extraordinary, non-recurring or prior-period income	2024	2023
Industry revenue from previous period	-	174,686
Dissolution of restricted funds	-	112,930
Other	182,662	142,673
Total extraordinary, non-recurring or prior period income	182,662	430,288

Our Partners



Our Sponsors



	Regular Individuals located in Europe (WHO definition)	EUR 250
	Corresponding Individuals located in non-European countries (WHO definition)	EUR 250
	Trainees & Postdoc Up to and including 35 years of age. Proof of age and trainee status required	EUR 50
	Undergraduate students Proof of enrolment required	Free
	Nurses & AHPs / Patients Proof of status required - Except for Patients	EUR 25
	Emeritus 65+ and EASL members for at least 10 years	EUR 25
	Emerging economy Proof of location of the home institution required	EUR 25
	Resource-limited economy Proof of location of the home institution required	Free

*Discover your membership
benefits now*




Become a member today



EASL CONGRESS

Barcelona Spain
27–30 May 2026



Save the date!

#EASLCongress

easlcongress.eu



EASL Office

Home of Hepatology

7 rue Daubin

1203 Geneva

Switzerland

+41(0)22 807 03 60

easlooffice@easlooffice.eu

www.easl.eu

